198TiP DEDALUS trial: A single-arm, phase II, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC. (December 2022) - Saddi, J.; Agustoni, F.; Arcangeli, S.; Cortinovis, D.L.; Ferrari, A.; Cicognini, D.; Klersy, C.; Pedrazzoli, P.; Malapelle, U.; Grossi, F.; Filippi, A.R.R.